Author "Troy, Kevin"

articles+ search results

125 articles+ results

1 - 20
View results as:
Number of results to display per page

1. Explaining Violent Intra-Ethnic Conflict: Group Fragmentation in the Shadow of State Power [2015]

  • Warren, T. Camber and Troy, Kevin K.
  • 59 J. Conflict Resol. 484 (2015) / Journal of Conflict Resolution, Vol. 59, Issue 3 (April 2015), pp. 484-509

2. Presentation of concurrent thrombotic thrombocytopenic purpura and Graves' disease [2022]

  • Casasanta, Nicole A., Shah, Nirali, Troy, Kevin, Edwards, Colleen, and Patel, Rima B.
  • Blood Coagulation & Fibrinolysis. October 1, 2022, Vol. 33 Issue 7, p422, 3 p.

3. Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies [2022]

  • Hussain, Maryam R., Ali, Faisal S., Verghese, Dhiran, Myint, Phyo Thazin, Ahmed, Mubashir, Gong, Zimu, Gerais, Yasmin, Siddiqui, Mahrukh, Lin, Jenny J., and Troy, Kevin
  • In Critical Reviews in Oncology / Hematology January 2022 169

4. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis [2020]

  • Naymagon, Leonard, Tremblay, Douglas, Zubizarreta, Nicole, Moshier, Erin, Troy, Kevin, Schiano, Thomas, and Mascarenhas, John
  • In Blood Advances 25 February 2020 4(4):655-666

5. Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19 [2021]

  • Lancman, Guido, Marcellino, Bridget K., Thibaud, Santiago, and Troy, Kevin
  • Annals of Hematology. 100(3):833-835

6. Soluble interleukin-2 receptor (sIL-2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosis [2020]

  • Naymagon, Leonard, Tremblay, Douglas, Troy, Kevin, and Mascarenhas, John
  • European Journal of Haematology. Sept 2020, Vol. 105 Issue 3, p255, 7 p.

7. The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis [2020]

  • Tremblay, Douglas, Naymagon, Leonard, Troy, Kevin, Cromwell, Caroline, Edwards, Colleen, Schiano, Thomas, and Kremyanskaya, Marina
  • Blood Coagulation & Fibrinolysis. April 2020, Vol. 31 Issue 3, p213, 6 p.

8. Plasma hemoglobin in COVID-19: authors’ reply [2021]

  • Lancman, Guido, Marcellino, Bridget K., Thibaud, Santiago, and Troy, Kevin
  • Annals of Hematology. 100(8):2127-2127

9. Hemophagocytic Lymphohistiocytosis Due to Primary HHV-8 Infection in a Liver Transplant Recipient [2018]

  • Cohen, Gabriel M., Langer, Arielle L., Sima, Hamid, Chang, Charissa, Troy, Kevin, and Taimur, Sarah
  • Transplantation Direct. Dec 01, 2018 4(12):e411-e411

10. Atypical hemolytic uremic syndrome associated with Capnocytophaga canimorsus [2017]

  • Sokol, Kelsey A., Veluswamy, Rajwanth R., Zimmerman, Brittney S., Tummalapalli, Sri Lekha, and Troy, Kevin
  • American Journal of Hematology. Mar 01, 2017 92(3):322-322

11. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study [2020]

  • Tremblay, Douglas, van Gerwen, Maaike, Alsen, Mathilda, Thibaud, Santiago, Kessler, Alaina, Venugopal, Sangeetha, Makki, Iman, Qin, Qian, Dharmapuri, Sirish, Jun, Tomi, Bhalla, Sheena, Berwick, Shana, Feld, Jonathan, Mascarenhas, John, Troy, Kevin, Cromwell, Caroline, Dunn, Andrew, Oh, William K., and Naymagon, Leonard
  • In Blood 2 July 2020 136(1):144-147

12. The emergence of methemoglobinemia amidst the COVID-19 pandemic [2020]

  • Naymagon, Leonard, Berwick, Shana, Kessler, Alaina, Lancman, Guido, Gidwani, Umesh, and Troy, Kevin
  • American Journal of Hematology. August 2020, Vol. 95 Issue 8, pE196, 2 p.

13. Multiple Myeloma in World Trade Center Responders: A Case Series [2009]

  • MOLINE, Jacqueline M, HERBERT, Robin, SAVITZ, David A, CROWLEY, Laura, TROY, Kevin, HODGMAN, Erica, SHUKLA, Gauri, UDASIN, Iris, LUFT, Benjamin, WALLENSTEIN, Sylvan, and LANDRIGAN, Philip
  • Journal of occupational and environmental medicine. 51(8):896-902
Subjects
Environment, Environnement, Hygiene and public health, epidemiology, occupational medicine, Hygiène et santé publique, épidémiologie, médecine du travail, Toxicology, Toxicologie, Sciences biologiques et medicales, Biological and medical sciences, Sciences medicales, Medical sciences, Immunopathologie, Immunopathology, Immunodéficits. Immunoglobulinopathies, Immunodeficiencies. Immunoglobulinopathies, Immunoglobulinopathies, Hemopathies, Hematologic and hematopoietic diseases, Leucémies. Lymphomes malins. Réticuloses malignes. Hématodermies. Splénomégalie myéloïde, Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis, Cancer, Cáncer, Hémopathie maligne, Malignant hemopathy, Hemopatía maligna, Immunoglobulinopathie, Immunoglobulinopathy, Inmunoglobulinopatía, Immunopathologie, Immunopathology, Inmunopatología, Médecine du travail, Occupational medicine, Medicina ocupacional, Syndrome lymphoprolifératif, Lymphoproliferative syndrome, Linfoproliferativo síndrome, Exposition professionnelle, Occupational exposure, Exposición profesional, Homme, Human, Hombre, Industrie construction, Construction industry, Industria construcción, Myélome, Myeloma, Mieloma, Reconstruction, Reconstrucción, Secouriste, Rescuer, Socorrista, and Attentats 11 septembre 2001
Abstract
Objectives: We report on cases of multiple myeloma (MM) observed in World Trade Center (WTC) responders registered in the WTC Medical Program. Methods: Possible cases of MM diagnosed between September 11, 2001, and September 10, 2007, in responders were confirmed if they met the World Health Organization and Mayo Clinic diagnostic criteria. Results: Among 28, 252 responders of known sex and age, eight cases of MM were observed (6.8 expected). Four of these cases were observed in responders younger than 45 years at the time of diagnosis (1.2 expected). A slight deficit of MM cases was observed in responders older than 45 years (4 observed, 5.6 expected). Conclusion: In this case series, we observe an unusual number of MM cases in WTC responders under 45 years. This finding underscores the importance of maintaining surveillance for cancer and other emerging diseases in this highly exposed population.

14. Autoimmune disease is a risk factor for the development of non-Hodgkin's lymphoma [2005]

  • CUTTNER, Janet, SPIERA, Harry, TROY, Kevin, and WALLENSTEIN, Sylvan
  • Journal of rheumatology. 32(10):1884-1887
Subjects
Rheumatology, Rhumatologie, Sciences biologiques et medicales, Biological and medical sciences, Sciences medicales, Medical sciences, Pathologie osteoarticulaire, Diseases of the osteoarticular system, Hemopathies, Hematologic and hematopoietic diseases, Leucémies. Lymphomes malins. Réticuloses malignes. Hématodermies. Splénomégalie myéloïde, Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis, Hémopathie maligne, Malignant hemopathy, Hemopatía maligna, Lymphoprolifératif syndrome, Lymphoproliferative syndrome, Linfoproliferativo síndrome, Epidémiologie, Epidemiology, Epidemiología, Facteur risque, Risk factor, Factor riesgo, Lymphome non hodgkinien, Non Hodgkin lymphoma, Linfoma no Hodgkin, Maladie autoimmune, Autoimmune disease, Enfermedad autoinmune, Rhumatologie, Rheumatology, Reumatología, and AUTOIMMUNE DISEASE NON-HODGKIN'S LYMPHOMA EPIDEMIOLOGY
Abstract
Objective. To investigate the relationship of prior autoimmune disease to the development of non-Hodgkin's lymphoma (NHL). Methods. Patients with NHL (n = 278) seen from 1993 to 2002 were compared with a group of patients with other hematological disorders (controls, n = 317) seen at the same time. All patients were questioned about prior autoimmune disease. Comparisons between NHL patients and controls were based on analysis of a 2 x 2 table of counts using Fisher's exact test. Analysis of the effect of autoimmune disease on NHL status, controlling for other risk factors, was performed using logistic regression. Results. Thirty-six (13%) NHL patients had a prior autoimmune disease compared to 5% of controls (p = 0.001). Sixty-nine percent of NHL patients with a prior autoimmune disease were female compared to 43% without a prior autoimmune disease, and this was similar in control patients, 69% and 48%, respectively. Twenty percent of all women with NHL had a history of autoimmune disease compared to 7% of women in the control group (p = 0.001). Nineteen of the NHL patients with autoimmune disease (56%) received immunosuppressive treatment compared to 5 (38%) in the controls. Conclusion. Autoimmune disease may account in part for the increase in NHL, especially in women.

15. Primary splenic lymphoma: Report of 10 cases using the REAL classification [2002]

  • GROSSKREUTZ, Celia, TROY, Kevin, and CUTTNER, Janet
  • Cancer investigation. 20(5-6):749-753
Subjects
Medical oncology, Cancérologie, Pharmacology drugs, Pharmacologie, galénique, Sciences biologiques et medicales, Biological and medical sciences, Sciences medicales, Medical sciences, Hemopathies, Hematologic and hematopoietic diseases, Leucémies. Lymphomes malins. Réticuloses malignes. Hématodermies. Splénomégalie myéloïde, Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis, Hémopathie maligne, Malignant hemopathy, Hemopatía maligna, Lymphome non hodgkinien, Non Hodgkin lymphoma, Linfoma no Hodgkin, Lymphoprolifératif syndrome, Lymphoproliferative syndrome, Linfoproliferativo síndrome, Rate pathologie, Splenic disease, Bazo patología, Anticancéreux, Antineoplastic agent, Anticanceroso, Efficacité traitement, Treatment efficiency, Eficacia tratamiento, Facteur risque, Risk factor, Factor riesgo, Homme, Human, Hombre, Lymphome grande cellule, Large cell lymphoma, Linfoma célula grande, Métastase, Metastasis, Metástasis, Pronostic, Prognosis, Pronóstico, Rate, Spleen, Bazo, Stade clinique, Clinical stage, Estadio clínico, Traitement, Treatment, Tratamiento, Classification REAL, and Revised European American Lymphoma classification
Abstract
Primary splenic lymphoma (PSL) is rare with a reported incidence of less than 1%. Diffuse large cell pathology has been reported in 22-33% of the cases and is felt to have a poor outcome. We report our experience in patients with PSL seen at Mount Sinai Medical Center during the years 1994-1999. Our objective was to evaluate staging (using the Ahmann and Kehoe criteria), prognosis using the International Prognostic Index (IPI), and pathology using the Revised European-American Lymphoma Classification (REAL) classification. Ten patients were identified. Eight of the 10 patients had diffuse large cell lymphoma (DLCL). Using the IPI, four patients were categorized as low risk, three as low/intermediate risk, and three as high risk. The only two deaths occurred in the high-risk group. Lymph node involvement beyond the splenic hilum seen by imaging studies represents an advanced non-Hodgkin's lymphoma and should be included no longer in the staging of PSL. Nine of the 10 underwent a splenectomy. Eight of the nine patients received chemotherapy following splenectomy. Seven of the nine patients remained in remission from I to 19 years. Splenectomy followed by combination chemotherapy, results in excellent long-term survival in PSL.

16. Non-Hodgkin's lymphoma in patients 70 years of age or older: factors associated with survival [2002]

  • CUTTNER, Janet, WALLENSTEIN, Sylvan, and TROY, Kevin
  • Leukemia research. 26(5):447-450
Subjects
Medical oncology, Cancérologie, Hematology, Hématologie, Sciences biologiques et medicales, Biological and medical sciences, Sciences medicales, Medical sciences, Hemopathies, Hematologic and hematopoietic diseases, Leucémies. Lymphomes malins. Réticuloses malignes. Hématodermies. Splénomégalie myéloïde, Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis, Homme, Human, Hombre, Hémopathie maligne, Malignant hemopathy, Hemopatía maligna, Lymphoprolifératif syndrome, Lymphoproliferative syndrome, Linfoproliferativo síndrome, Age, Edad, Facteur risque, Risk factor, Factor riesgo, Lymphome non hodgkinien, Non Hodgkin lymphoma, Linfoma no Hodgkin, Personne âgée, Elderly, Anciano, Pronostic, Prognosis, Pronóstico, Survie, Survival, and Sobrevivencia
Abstract
The incidence of non-Hodgkin's lymphoma (NHL) has increased dramatically especially in persons over 60 years of age. We reviewed our experience in patients with NHL who were 70 years of age or older and seen between 1992 and 1998 in an effort to find any unique risk factors in this age group. There were 64 patients. Twenty-five had indolent disease and 38 had aggressive disease. The majority of patients with indolent lymphoma presented with nodal disease and were more likely to have bone marrow involvement. In contrast, 71% of patients with aggressive lymphoma presented with extra-nodal disease. Five of seven (71%) patients with indolent and 22 of 29 (76%) with aggressive NHL who received an Adriamycin containing regimen as first line therapy achieved a complete response. The International Prognostic Index (IPI) was a strong predictor of both survival (P < 001) and response (P = 007) for the group as a whole. The IPI accurately predicted the survival of patients with aggressive NHL (P = 026). This was not the case with indolent lymphomas. This study suggests that elderly patients with NHL are more likely to have aggressive disease, a diffuse pathology and an extra-nodal presentation.

17. Authors' Response [2009]

  • Moline, Jacqueline M., Herbert, Robin, Crowley, Laura, Troy, Kevin, Hodgman, Erica, Shukla, Gauri, Udasin, Iris, Luft, Benjamin, Wallenstein, Sylvan, Landrigan, Philip, and Savitz, David A.
  • Journal of Occupational and Environmental Medicine. 51(12):1357-1358

18. This title is not available for guests. Log in to see the title and access the article.

19. This title is not available for guests. Log in to see the title and access the article.

20. Explaining Violent Intra-Ethnic Conflict: Group Fragmentation in the Shadow of State Power [2015]

  • Warren, T. Camber, Troy, Kevin K., and Defense Analysis (DA)
Abstract
pre-print, forthcoming, Journal of Conflict Resolution Despite significant advances in the disaggregation of the study of civil conflict and inter-ethnic violence, intra-ethnic violence remains understudied. In this paper, we present the first systematic, cross-national analysis of the conditions that promote violent, fragmentary conflict within politically active ethnic minorities. We propose a model of intra-ethnic conflict in which collective violence is produced by the interaction between sub-group entrepreneurs and the suppressive actions of the state. This two-level model predicts a curvilinear relationship between the relative size of an ethnic minority and its probability of experiencing large-scale intra-ethnic conflict. Additional hypotheses based on the proposed causal mechanism are also posited. These hypotheses are tested with data drawn from a global sample of politically active ethnic minorities, for the period 1990 - 2006, using a combination of parametric and semi-parametric regression techniques. The results strongly confirm the predicted curvilinear relationship, while also demonstrating that the specific shape of this relationship shifts in predictable ways under varying social and political contexts. Portions of this research were funded by support from the Niehaus Center for Globalization and Governance at Princeton University, and the Center for "Coping with Crises in Complex Socio-Economic Systems" at ETH Zurich.

Catalog

Books, media, physical & digital resources
See catalog results

Guides

Course- and topic-based guides to collections, tools, and services.
Search ""Troy, Kevin"" in all guide pages